Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nastech Pharmaceutical has changed its name to MDRNA. As part of its new corporate and scientific focus, MDRNA has named Michael French, formerly of Sirna Therapeutics, as CEO, effective June 23, 2008.
Subscribe to our email newsletter
Mr French succeeds Steven Quay, who has been appointed chief scientific officer and chairman of MDRNA’s scientific advisory board and will remain chairman of the board of directors.
Mr French was senior vice president of corporate development at Sirna Therapeutics from 2005 until 2007 when the company was acquired by Merck.
MDRNA said that it will leverage its scientific and intellectual property (IP) position surrounding the research, development and delivery of Dicer substrates and ‘Meroduplex’ (mdRNA) RNA interference (RNAi) drug candidates to build an industry-leading position in the development and commercialization of RNAi-based therapeutics.
In addition to its license through the City of Hope to Dicer substrate IP, MDRNA will leverage its portfolio of delivery IP, including an issued patent on the ‘Trp Cage’ phage display library for generating tissue-homing peptides.